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Background:Molecular characterization of NSCLC has improved significantly in the
last few years and multigenes diagnostic platforms spread in clinical molecular
laboratories for the advantage of their multiplexed approach added to the requirement
of a very low amount of DNA, compared to conventional methods. The main goal for
NSCLC sampling management is the optimization of either cytological and histological
specimens to guarantee immunophenotyping of the tumour with all genomic data for
targeted therapies. However, DNA yield is often very critical and low tumour cells
enrichment requires high analytical sensitivities.
Methods: In the period January 2014-March 2016, we genotyped 438 NSCLC by
multiplexed mass spectrometry on Agena MassARRAY® System (Agena Bioscience)
with CE-IVD Myriapod® Lung status kit (Diatech Pharmacogenetics), a target assay
that investigates more than 230 mutations on 10 genes involved in NSCLC, with a
DNA amount of at least 40 ng. In 35% of cases, cytological samples were the only
available diagnostic material.
Results: In 102 (23.3%) samples the amount of DNA extracted would have been
insufficient for EGFR testing by RealTime PCR or pyrosequencing, and they would had
been classified as “not adequate”. We processed these cases by mass spectrometry
observing EGFR and KRAS mutations in 12 (11.8%) and 30 (29.4%) cases, respectively.
Among all cases we observed 12 (2.7%) tumours with neoplastic cell content lower
than 30% that didn’t revealed any mutation in EGFR/KRAS. We classified these
patients as “inadequate for molecular testing”, recommending a retest on a more
representative sampling of the lesion.
Conclusions: Combining a sensitive multiplexed mass spectrometry approach with an
efficient management of the sample, the diagnostic accuracy was 97.3%. This value
would had been decreased to 76.7% if only Real Time or sequencing methods were
available. Considering the generally mutual presence of EGFR/KRAS mutations and
ALK rearrangements we avoid a further diagnostic bronchoscopic exam to 42 patients.
Cooperation between pneumologist, pathologist, molecular biologist and oncologist is
essential for the management of NSCLC patients.
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